SynthesisCNS neuroscience & therapeutics2021
Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence.
Synthesis in CNS neuroscience & therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence.CNS neuroscience & therapeutics · 2021Pooled it
- Barriers to long-acting injectable antipsychotic use for community-dwelling patients with schizophrenia in China: a qualitative process analysis.BMC psychiatry · 2026Article
- Akkermansia muciniphila Alleviates Olanzapine-Induced Hepatic Steatosis via the Gut Microbiota-IGFBP2/APOA1-Liver Axis.Microbial biotechnology · 2025Article
- A multidimensional assessment of adverse events associated with paliperidone palmitate: a real-world pharmacovigilance study using the FAERS and JADER databases.BMC psychiatry · 2025Article
- Public mental health services in Southern China and related health outcomes among individuals living with severe mental illness.Global health research and policy · 2024Article
- Effect of Group Cognitive Behavioral Therapy on Patients with Early-Onset Schizophrenia.Alpha psychiatry · 2024Article
- Examining clinician choice to follow-up (or not) on automated notifications of medication non-adherence by clinical decision support systems.BMC medical informatics and decision making · 2023Article
- Predictors of admission to an assertive outreach service for psychosis in Lebanon.PLOS global public health · 2022Article
- Corrigendum.CNS neuroscience & therapeutics · 2021Article
Corrections and comments
- Erratum issuedCorrigendum.2021
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent research on second-generation long-acting injectable antipsychotics (LAI SGAs) has proven its effectiveness in minimizing medication nonadherence problem and reducing relapses. Administered by medical professionals, making quick detection of nonadherence possible, long-acting injectable antipsychotics (LAIs) facilitate immediate intervention and recovery process, and thus are favored by psychiatrists. Despite a higher initial cost with LAIs, the subsequent schizophrenia-related health costs for hospitalizations and outpatients are greatly reduced. With reference to guidelines published by psychiatric associations around the globe, this article looks at scenarios in Hong Kong on the management of severe mentally ill patients with regard to the use of a host of psychosocial interventions as well as LAI SGAs as a preferable treatment. In particular, it examines the benefits of using LAI SGAs for Hong Kong patients who demonstrated high nonadherence treatment rates due to their social environment. It assesses the rationale behind the early usages of LAI SGAs, which help to provide better recovery outcomes for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.